For a long time, the global pharmaceutical industry followed a relatively clear development path—driven by single blockbuster drugs. A successful drug could sustain a company’s growth for years, even over a decade. From statins to PD-1/PD-L1 immunotherapies, this model has been repeatedly validated across different eras.
However, after 2025, this logic is undergoing profound...
Italiano 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek